Evidence map›Paper›PMID 42400697›Full record

ArticleJournal of medical systems2026

AI-enabled clinical decision support in breast cancer care: a blinded multicenter benchmarking study comparing medically specialized with a general-purpose system.

Jonas Freudenberg, Johannes Knitza, Niklas Gremke, Niklas Amann, Thomas M Deutsch, Nikolas Tauber, Kerstin Muras, Zoe S Oftring, Tobias Engler, Alexander Englisch and 10 more

Abstract readMulticenter StudyComparative Study
In one paragraph

Article in Journal of medical systems, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Jonas FreudenbergPhilipps-Universität Marburg, School of Medicine, Institute for Digital Medicine, Marburg, Germany.ORCID http://orcid.org/0009-0003-7156-9069
Johannes KnitzaPhilipps-Universität Marburg, School of Medicine, Institute for Digital Medicine, Marburg, Germany.ORCID http://orcid.org/0009-0005-9192-4026
Niklas GremkePhilipps-Universität Marburg, School of Medicine, Clinic for Gynecology and Obstetrics, Marburg, Germany.ORCID http://orcid.org/0000-0002-9015-3646
Niklas AmannErlangen University Breast Center, University Hospital Erlangen, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.ORCID http://orcid.org/0009-0005-5280-2800
Thomas M DeutschUniversity Hospital Heidelberg, Heidelberg University Breast Center, University of Heidelberg, Heidelberg, Germany.
Nikolas TauberLuebeck University Breast Center, University Hospital Schleswig-Holstein, University of Luebeck, Campus Luebeck, Luebeck, Germany.ORCID http://orcid.org/0009-0001-4592-2151
Kerstin MurasLuebeck University Breast Center, University Hospital Schleswig-Holstein, University of Luebeck, Campus Luebeck, Luebeck, Germany.
Zoe S OftringPhilipps-Universität Marburg, School of Medicine, Institute for Digital Medicine, Marburg, Germany.
Tobias EnglerTuebingen University Breast Center, University Hospital Tuebingen, Eberhard Karls University of Tuebingen, Tuebingen, Germany.ORCID http://orcid.org/0000-0002-8063-2053
Alexander EnglischTuebingen University Breast Center, University Hospital Tuebingen, Eberhard Karls University of Tuebingen, Tuebingen, Germany.
Stefan LukacDepartment of Obstetrics and Gynecology, University Hospital Ulm, University of Ulm, Ulm, Germany.ORCID http://orcid.org/0000-0002-9336-2267
Adriano FabiDepartment of Plastic, Reconstructive, Aesthetic and Hand Surgery Basel, University Hospital of Basel, Basel, Switzerland.ORCID http://orcid.org/0009-0003-2605-7398
André S AlvesDepartment of Surgery, University Hospital of Geneva, University of Geneva, Geneva, Switzerland.
Kristin ReinhardtHalle-Wittenberg University Breast Center, University Hospital Halle (Saale), Martin Luther University of Halle-Wittenberg, Halle (Saale), Germany.
Markus WallwienerHalle-Wittenberg University Breast Center, University Hospital Halle (Saale), Martin Luther University of Halle-Wittenberg, Halle (Saale), Germany.
Moritz KuhlmannPhilipps-Universität Marburg, School of Medicine, Institute for Digital Medicine, Marburg, Germany.ORCID http://orcid.org/0009-0003-5922-3559
Jonathan BambergerPhilipps-Universität Marburg, School of Medicine, Institute for Digital Medicine, Marburg, Germany.ORCID http://orcid.org/0009-0002-2160-6418
Uwe WagnerPhilipps-Universität Marburg, School of Medicine, Clinic for Gynecology and Obstetrics, Marburg, Germany.
Sebastian KuhnPhilipps-Universität Marburg, School of Medicine, Institute for Digital Medicine, Marburg, Germany.ORCID http://orcid.org/0000-0002-8031-2973
Sebastian GriewingPhilipps-Universität Marburg, School of Medicine, Institute for Digital Medicine, Marburg, Germany. s.griewing@uni-marburg.de.ORCID http://orcid.org/0000-0001-5355-8903

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Medically specialized AI systems that have obtained regulatory clearance as medical devices can be deployed for patient-specific clinical decision support under defined compliance requirements. However, it remains unclear whether medical specialization and regulatory status translate into higher-quality breast cancer treatment recommendations than those produced by a general-purpose large language model (LLM). This blinded, multicenter study compared the performance of two medically specialized AI systems with a general-purpose model in breast cancer care. Two medically specialized (Prof. Valmed and OpenEvidence) and one general-purpose system (ChatGPT-5 Thinking) were prompted to generate treatment plans for 20 standardized breast cancer patient cases. Outputs were rated and ranked by blinded, board-certified breast cancer specialists from seven university breast cancer centers for safety, guideline adherence, medical adequacy, completeness, overall quality, and logical coherence. Statistical analyses comprised descriptive statistics, inter-rater reliability assessment, non-parametric performance comparisons of rating and ranking outcomes, and correlation analyses. Mean (± standard deviation) processing time for ChatGPT-5 Thinking (159 ± 58 s) was more than fourfold higher than that of Prof. Valmed (35 ± 4) and OpenEvidence (9 ± 1). ChatGPT-5 Thinking achieved significantly higher ratings across all evaluation categories, with no significant differences between the two medically specialized systems. Treatment plans generated by ChatGPT-5 Thinking were ranked as the top choice in 96.4% of rater-case combinations, compared with 3.6% for OpenEvidence, while Prof. Valmed was never ranked first. In this blinded, multicenter evaluation, a general-purpose LLM outperformed two medically specialized, retrieval-augmented systems in generating breast cancer treatment plans across all assessed categories. These results indicate that while regulatory clearance and domain specialization address key requirements for AI-enabled clinical decision support systems, these factors alone do not translate into superior performance in breast cancer care. At present, medically specialized systems may be best used as supportive tools under expert oversight, while further optimization and real-world validation are needed.Clinical trial number: Not applicable.

Indexed as

Artificial IntelligenceBreast NeoplasmsDecision Support Systems, ClinicalBenchmarkingFemaleHumansIntelligent SystemsLarge Language ModelsReproducibility of ResultsArtificial intelligenceBenchmarking studyBreast cancerClinical decision supportLarge language models

Identifiers

PMID42400697
PMCPMC13332881

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.